Quotient Bioscience Group receives 35m pound strategic investment

Quotient Bioscience Group is to embark on an acquisition-led growth strategy after securing a "significant minority investment" of 35 million pounds from private equity firm TA Associates.

The company, which specialises in early-stage drug development, analytical services and drug surveillance processes for sport, said it will use the new backing to expand its market share in both North America and Europe.

It builds on a previous acquisition strategy that has seen Quotient make four additions to the group since January 2007 – HFL Sport Science, Alba Bioscience, GR Micro and BioDynamics Research.

The group has also recently consolidated its drug development services under the banner of Quotient Bioresearch, which employs more than 312 people at sites in Newmarket, Rushden and London.

The firm’s chairman and chief executive officer Paul Cowan said: "Completion of this investment will enable us to continue funding growth through synergistic acquisitions and organic growth in our existing core businesses."